Resources
52 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 10/21/2020 (updated 9/2/2021)
This study sought to identify best practices for retaining individuals in treatment and for achieving continuity of care between settings.
Posted 10/23/2020 (updated 9/2/2021)
The goal of this module is to train providers to initiate patients on buprenorphine safely and effectively.
Posted 10/23/2020 (updated 9/2/2021)
This article offers data regarding offering buprenorphine treatment at a public hospital primary care setting using a home, unobserved induction protocol.
Posted 10/23/2020 (updated 9/2/2021)
The objective of this report was to perform a systematic review of the beneficial and harmful effects of BUP-ER 100 mg and 300 mg for the management of moderate-to-severe OUD in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product.
Posted 10/23/2020 (updated 9/2/2021)
These pilot study results suggest comparable safety and effectiveness of unobserved and office induction and point toward utilization of non-inferiority design during future definitive protocol development.
Posted 10/23/2020 (updated 9/2/2021)
The American Society of Addiction Medicine (ASAM) developed this National Practice Guideline for the Treatment of Opioid Use Disorder to provide information on evidence-based treatment of opioid use disorder.
Posted 12/2/2020 (updated 9/2/2021)
This Association of Maternal & Child Health Programs (AMCHP) issue brief discusses the challenges and opportunities in providing rural community care to women with mental health and substance use treatment needs.
Posted 2/18/2021 (updated 9/2/2021)
Opioid use disorder (OUD), a chronic disease, is a major public health problem. Despite availability of effective treatment, too few people receive it and treatment retention is low. Understanding barriers and facilitators of treatment access and retention is needed to improve outcomes for people with OUD.
In this study we sought to assess 3-month outcomes from a patient-centered practice that included MAT with buprenorphine or naltrexone plus the option to participate in psychosocial treatments. The psychosocial treatments included case management, psychotherapy, peer recovery groups such as Narcotics Anonymous or Smart Recovery, or peer support through a local harm reduction program.
Posted 3/25/2021 (updated 9/2/2021)
Considerations for Addressing Neonatal Abstinence Syndrome (NAS)
Dr. Lopata, JBS NAS Technical Expert Leads, and NAS RCORP grantees from the Western Regions will discuss resources, stigma, best practices, and challenges in addressing NAS.
Posted 4/12/2021 (updated 9/2/2021)
The National Center on Substance Abuse and Child Welfare (NCSACW), a program of the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Administration on Children, Youth and Families (ACYF), prepared this document to support policy makers, administrators, and service providers. The goal of the document is to foster collaborative responses across multiple systems to improve safety, permanency, and well-being outcomes for infants, recovery for their parents, and to meet the needs of families and caregivers.